Until now, studies utilizing mRNA electroporation as a tool for the delivery of tumor antigens to human monocyte-derived dendritic cells (DC) have focused on DC electroporated in an immature state. Immature DC are considered to be specialized in antigen capture and processing, whereas mature DC present antigen and have an increased T-cell stimulatory capacity. Therefore, the consensus has been to electroporate DC before maturation. We show that the transfection efficiency of DC electroporated either before or after maturation was similarly high. Both immature and mature electroporated DC, matured in the presence of an inflammatory cytokine cocktail, expressed mature DC surface markers and preserved their capacity to secrete cytokines and chemokines upon CD40 ligation. In addition, both immature and mature DC can be efficiently cryopreserved before or after electroporation without deleterious effects on viability, phenotype or T-cell stimulatory capacity including in vitro antigen-specific T-cell activation. However, DC electroporated after maturation are more efficient in in vitro migration assays and at least as effective in antigen presentation as DC electroporated before maturation. These results are important for vaccination strategies where an optimal antigen presentation by DC after migration to the lymphoid organs is crucial. Gene Therapy (2005) 12, 772-782.
Introduction
For the generation of an effective therapeutic cancer vaccine, it is necessary to load tumor antigens onto antigen-presenting cells and to present antigens in the appropriate immune stimulatory environment to induce a strong antigen-specific CD4 + T-helper and CD8 + cytotoxic T-cell response. 1, 2 Dendritic cells (DC) are highly specialized antigen-capturing, -processing and -presenting cells of the human body with the unique capacity to establish and control primary immune responses because they have the highest surface density of MHC and costimulatory molecules, together with a high motility, which allows them to traffic from the site of antigen uptake to the T-cell areas of lymph nodes, and they have the ability to produce immunostimulatory cytokines and chemokines. [3] [4] [5] [6] [7] [8] All this knowledge has led to the use of DC as natural adjuvants to immunize cancer patients against tumor-specific self-antigens and to break T-cell tolerance against these tumor antigens. [9] [10] [11] [12] [13] Normally, circulating DC are present in extremely small numbers in human blood and difficult to maintain in culture. Therefore, we designed a reproducible method for the generation of large numbers of DC in a semiclosed culture system using Cell Factories. 14 This method is based on the generation of immature DC from adherent peripheral blood monocytes after several days of culture in the presence of IL-4 and GM-CSF 15 followed by an incubation step with specific maturation inducing inflammatory cytokines. 16 Many different methods have been used to load DC with tumor-associated antigens (TAA) before in vivo vaccination. 17, 18 With regard to clinical applicability, nonviral antigen-loading strategies have been developed based on transfection of defined or full-spectrum tumor messenger RNA (mRNA) into DC. 19, 20 This approach has a number of advantages to peptide-or protein-based methods. 21, 22 It does not require the knowledge of the HLA haplotype of each patient and the corresponding HLA-binding epitopes of the TAA. 23 Another advantage is the ability to modify the TAA with targeting signals in order to obtain better MHC class I and class II presentation. [24] [25] [26] [27] [28] [29] [30] Gilboa and colleagues have pioneered this approach in the human system and have successfully delivered mRNA into DC in different cancer systems. They have shown that mRNA-transfected DC are able to stimulate tumor antigen-specific cytotoxic T lymphocytes (CTL) in colon, prostate, renal and cervical cancer. [31] [32] [33] [34] [35] [36] Recent research developments indicate that electroporation of in vitro-transcribed mRNA into human DC may be an even more promising strategy to load DC. switch in chemokine receptors. This phenotype offers mature DC the capacity to migrate to the lymph nodes and to present antigenic epitopes to CD4 + and CD8 + T lymphocytes leading to an antigen-specific T-cell response. It has been shown that mature DC are potent stimulators of T cells in vitro. 43 Therefore, it is a prerequisite for the development of a DC-based cancer vaccine to obtain mature DC. Most groups have used immature DC for loading with mRNA either by passive pulsing, lipofection or electroporation. We analyzed the possibility to electroporate DC after induction of their mature phenotype.
The purpose of this study was to compare the phenotypic and functional properties of DC electroporated with mRNA in an immature or a mature state. Therefore, we evaluated the yield, viability, possibility to freeze, phenotype, cytokine/chemokine production profile and the migratory, antigen-presenting and specific T-cell-activating capacity of DC electroporated either before or after maturation. Furthermore, the presentation of MAGE-A3-derived epitopes in the context of both HLA class I and class II molecules by DC electroporated after maturation was compared with mature peptidepulsed DC at different time points. We postulate that mature DC frozen before electroporation are ideal candidates for immunotherapy in cancer patients.
Results
Electroporation efficiency and viability of DC electroporated either before or after maturation are comparable
To investigate which DC differentiation state is optimal for transfection, immature and mature DC were electroporated with in vitro-synthesized mRNA using a previously optimized protocol. 40 As described in Materials and methods, DC were electroporated on day 6 of DC culture with eGFP or tNGFR encoding mRNA and matured with the inflammatory cytokine cocktail either 24 h before or 4 h after electroporation ( Figure 1 for the timing of the different manipulations of the cells). The percentage of transgene-expressing cells was equal when the cells were transfected with either eGFP or tNGFR encoding mRNA (data not shown). As shown in Table 1 , the electroporation efficiency of immature and mature DC was very similar (89.172.9% for immature DC and 93.471.2% for mature DC, n ¼ 8). Electroporation did not damage the cells (the viability 24 h after electroporation was 93.874.3% for immature DC and 95.272.4% after electroporation of mature DC, n ¼ 8). From these experiments, we can conclude that there is no significant difference in transgene expression and viability between DC electroporated either before or after maturation.
We observed that the yield of electroporated DC relative to the starting number of peripheral blood mononuclear cells (PBMC) was double when the DC were electroporated after maturation (4.870.3% of the input PBMC for mature electroporated DC versus 2.170.4% for DC that were first electroporated and then induced to their mature phenotype; P ¼ 3 Â 10
À5
, n ¼ 4). The eGFP reporter gene was used to assess the level of transgene expression up to 5 days after the electroporation. A large fraction of the DC electroporated in their immature or mature state still expressed eGFP 5 days after electroporation (Figure 2 ). Similar results were obtained when tNGFR was used as reporter protein (data not shown). At 4 h after electroporation, we found that the percentage of eGFP-positive DC was significantly higher (P ¼ 0.009, n ¼ 3) when mature DC were used. At later time points after electroporation, no significant differences in the fraction of eGFP-expressing cells or in the expression level as indicated by MFI were observed.
As the possibility to freeze large numbers of DC would be a major advantage for their use in cancer immunotherapy, 44, 45 we investigated whether electroporation could be performed efficiently after cryopreservation of either immature or mature DC. As outlined in Figure 1 , immature and mature DC were frozen either before or after electroporation. Immature DC used for electroporation either before or after storage in liquid nitrogen were induced to mature before flow cytometric We also investigated the immunophenotype of these cells. DC cultured in the presence of the inflammatory cytokine cocktail, either before or after electroporation, induced a typical immunophenotype profile of mature DC ( Figure 3a ). As compared with DC that had been electroporated in an immature state and matured for 24 h, DC that had been matured before electroporation displayed significant (Pp0.013, n ¼ 4) higher levels of CD80, CD83, CD25, CD40 and CCR7. The timing of cryopreservation, with respect to electroporation and maturation, had no negative effects on the capacity of DC to express the maturation markers (data not shown).
Higher expression levels of the markers CD80, CD83 and CCR7 were displayed by the DC that had been matured before electroporation when compared to DC that had been electroporated in their immature state and had also been cultured for 48 h in the presence of the maturation inducers (Figure 3b ; Pp0.043, n ¼ 4). Immature DC were first electroporated and 4 h later induced to mature for 48 h (E-M48; black bars). Flow cytometry was performed after maturation induction. DC matured for 24 h were electroporated and further cultured in the maturation mix for an additional 24 h before analysis (M-E; white bars). All data are expressed as mean7s.d. of four independent experiments. The significant difference is indicated with an asterisk (*). (Figure 4a ). Immature and mature DC that had been frozen either before or after electroporation had a similar allostimulatory capacity (data not shown).
We further investigated whether DC electroporated either before or after maturation retained their capacity to secrete cytokines and chemokines upon CD40 ligation in the presence of IFN-g. Therefore, immature and mature DC were electroporated with mRNA. At 4 h after electroporation, immature DC were matured for 48 h with the cytokine cocktail, similar to the DC that had been electroporated in their mature state and analyzed after an additional 24 h culture in the maturation mix. Immature DC electroporated and subsequently matured for 24 h were included for comparison. We could detect neither IL-4 nor IFN-a secretion for DC electroporated under either condition. Secretion of IL-12p70, IL-6, IL-8, MIP-1a, MIP-1b and MIP-3b did not differ significantly between DC electroporated either before or after maturation ( Figure 4b ). However, we observed a reduced TNF-a secretion upon CD40 ligation by DC matured for 48 h compared to DC matured for 24 h. This difference was statistically significant (Pp0.001, n ¼ 6). Without further activation (CD40 ligation+IFN-g), lower levels of IL-6, IL-8, MIP-1a, MIP-1b and MIP-3b were produced by the DC electroporated before and after maturation (data not shown).
Because of the high expression of CCR7 by the DC electroporated before and after maturation, we investigated their responsiveness to the CCR7 ligand MIP-3b, using a transwell system. Briefly, frozen immature and mature DC were thawed and electroporated with mRNA. At 4 h after electroporation, immature DC were matured with the cytokine cocktail for 24 or 48 h. As shown in Figure 4c , DC electroporated after maturation showed a significantly (P ¼ 0.014, n ¼ 3) higher migratory capacity (when expressed as the percentage of input DC) compared to DC electroporated before a 24 h maturation induction. However, DC electroporated before and after maturation migrated in response to MIP-3b to the same extent when the results were presented as chemotactic index, defined as the fold increase in cell migration in the presence of CCR7 ligand compared to spontaneous cell migration (data not shown). An additional 24 h maturation of the immature electroporated DC did not significantly affect their migratory capacity.
DC electroporated before and after maturation are capable of processing and presenting a well-defined antigen epitope
We investigated whether DC expressing sig-MAGE-A3-Lamp1 after electroporation either before or after maturation, on the one hand, and before or after storage in liquid nitrogen, on the other hand, were able to stimulate an HLA class II-restricted MAGE-A3-specific (M3-DP4) T-cell clone. The results of these experiments are presented in Figure 5 . These data clearly indicate that the HLA-DP4-restricted MAGE-A3 epitope is efficiently processed and presented by all the transfected DC when electroporated either in their immature or mature differentiation state before or after freezing of the cells. However, DC electroporated after maturation both before and after storage in liquid nitrogen were more potent stimulators of the M3-DP4-specific T cells than DC electroporated before maturation (for DC frozen before electroporation, P ¼ 0.006, n ¼ 3; for DC frozen after electroporation, P ¼ 0.003, n ¼ 3). Whether the DC were frozen before or after electroporation did not influence their T-cell stimulatory capacity. DC electroporated with irrelevant mRNA or pulsed with irrelevant peptide were Optimizing mRNA electroporation in dendritic cells A Michiels et al unable to induce IFN-g secretion by the M3-DP4-specific T cells (data not shown).
Kinetics of the T-cell stimulatory capacity of electroporated DC and peptide-pulsed DC after maturation
We compared the kinetics of the T-cell stimulatory capacity of the electroporated mature DC to peptidepulsed mature DC. Therefore, frozen mature DC were thawed and electroporated with sig-MAGE-A3-Lamp1 mRNA, pulsed with 10 mg/ml M3-DP4 or 10 mg/ml M3-A1 peptide. At 0.5, 24, 48 and 72 h after antigen loading, the electroporated DC or peptide-pulsed DC were cocultured with M3-DP4-or M3-A1-specific T-cell clones for 20 h and the IFN-g release in the supernatant was measured by ELISA. DC electroporated with irrelevant mRNA or pulsed with irrelevant peptides were used as negative controls. These data, summarized in Figure 6 , show that the HLA class II-restricted antigen presentation capacity of the electroporated DC is comparable with the peptide-pulsed DC (Figure 6a ). The HLA class II-peptide complexes are stable for at least 72 h. In the HLA class I-restricted MAGE-A3 presentation assay, we showed that antigen-loaded DC lost their T-cell stimulatory capacity already after 48 h but that the stimulation of the M3-A1-specific CTL clone by the electroporated DC remained significantly higher (P ¼ 0.002, n ¼ 3) at 24 h after loading compared to the peptide-pulsed DC (Figure 6b ).
Kinetics of mRNA levels in DC electroporated after maturation
We studied the kinetics of mRNA levels present in DC electroporated after maturation. We performed a quantitative RT-PCR analysis for MAGE-A3 on RNA extracted from mature DC electroporated with sig-MAGE-A3-Lamp1 mRNA (Table 3) . Kinetic analyses of MAGE-A3 mRNA expression in mature electroporated DC showed a maximum immediately after electroporation, followed by a decline as a function of time. Nevertheless, even at 72 h after electroporation, MAGE-A3 mRNA was still detectable.
In vitro stimulation of MelanA-A2-specific T lymphocytes by DC electroporated either before or after maturation is comparable DC electroporated with sig-MelanA-Lamp1 mRNA either in their immature or mature differentiation state, either before or after storage in liquid nitrogen, were compared for their capacity to induce a MelanA-specific (Figure 7) . No significant differences in antigen-specific T-cell activation were observed between DC electroporated in their immature or mature state, before or after freezing.
Discussion
Antigen-loaded DC are now intensively investigated as potential cellular antitumor vaccines. Several recent reports have indicated that loading of immature DC with whole tumor-derived mRNA or defined mRNA represents an effective nonviral strategy to stimulate T-cell responses both in in vitro and in vivo models. [32] [33] [34] [35] [36] [38] [39] [40] 42 In this study, we have used the recently described electroporation method to introduce defined mRNA into DC. Many factors may play an important role in the final outcome of this method. We investigated which DC differentiation state is most amenable for this method of transfection. Therefore, DC were electroporated with mRNA either before or after maturation by a previously optimized protocol yielding a transfection efficiency of up to 80%. 40 We here show that the transgene expression by DC electroporated with eGFP mRNA either before or after maturation is high, even at 120 h after electroporation. At 4 h after transfection, we observed a significantly higher transfection efficiency of DC electroporated in a mature state when compared to DC electroporated in an immature state. The reasons for this difference are not clear and should be further investigated. There might be a difference at the level of translation efficiency of mRNA to protein after electroporation into immature or mature DC. However, at 24 h after electroporation or later, we did not observe a significant difference in transgene expression and viability between DC electroporated either before or after maturation.
Moreover, we find that the yield of DC relative to the input PBMC is significantly higher when the cells are matured before the electroporation. It has been described 16, 46, 47 that immature DC can revert to macrophages in the absence or upon withdrawal of maturation stimuli, whereas terminally differentiated and matured DC are resistant to this reversion. As determined by light microscopy, cultures of immature electroporated DC had much higher percentages of strongly adherent cells compared to mature electroporated DC. Addition of the maturation-inducing cytokine cocktail 4 h after electroporation of the immature DC did not diminish this stickiness to the plastic ware. In addition, it is possible but less likely that a higher number of dead cells after the electroporation of immature DC was missed because the viability of DC was determined only 24 h after electroporation instead of immediately after electroporation. We conclude that a combination of strong adherence and possibly more cell death could explain the loss of almost half of the DC after electroporation in an immature state. In view of clinical trials and with the aim to obtain a maximum number of potent antigen-presenting cells from a single leukapheresis with minimal costs for differentiation and maturation factors, the electroporation of DC in a mature state seems to be preferable.
A prerequisite for the easy generation of DC vaccines is the ability to store the DC preparations in liquid nitrogen without harm to the DC and with preservation of their viability or function. 44, 45 We show that both immature and mature DC can be efficiently cryopreserved before or after electroporation without significant effect on their transgene expression or viability. We did not observe a significant difference in transgene expression or viability of the immature and mature DC frozen either before or after the electroporation.
The observed phenotypical properties are in accordance with previously reported data 40 using immature electroporated DC. We show that DC electroporated either before or after maturation acquire a mature phenotype and express high levels of CCR7, a key marker for the ability of DC to migrate to the secondary lymphoid organs. 48 Freezing and thawing of DC before or after electroporation did not have an influence on their maturation capacity. We also demonstrate that DC electroporated after maturation resulted in a slightly more mature phenotype. Even after an additional culture in the presence of the maturation-inducing cytokine cocktail of the immature electroporated DC, DC electroporated after maturation expressed higher levels of the CD80, CD83 and CCR7 molecules. This observation might indicate that the electroporation process does affect the maturation capacity of the immature DC.
Typical functional characteristics of mature DC include their capacity to vigorously stimulate allogeneic T cells, their capacity to produce cytokines and chemokines and their migratory capacity to CCR7-binding chemokines. We show that DC electroporated before and after maturation are strong inducers of an allogeneic T-cell response, even with low numbers of stimulator cells. Secretion of the cytokines IL-12p70 and IL-6 and the Figure 7 Induction of MelanA-specific T cells by DC electroporated before or after maturation and before or after storage in liquid nitrogen. Immature DC frozen, thawed, electroporated with MelanA-encoding mRNA and then matured (F/T-E-M) or immature DC first electroporated, matured and then stored (E-M24-F/T) or mature DC electroporated either before or after storage (M-E-F/T or M-F/T-E) were used to stimulate autologous T cells on day 0 and 7. At 7 days after the second stimulation, an ELISPOT assay was performed using peptide-loaded T2 cells as target cells. Data are expressed as mean7s.d. of triplicate samples from the same experiment. This figure is representative of three independent experiments.
Optimizing mRNA electroporation in dendritic cells A Michiels et al chemokines IL-8, MIP-1a, MIP-1b and MIP-3b after activation of DC did not differ significantly between immature and mature electroporated DC. The reduced TNF-a production upon CD40 ligation by the DC matured for 48 h compared to DC matured for only 24 h is not unexpected since TNF-a is produced at high levels only very early after stimulation. 49 Fundamental to the priming of T-cell immune responses in vivo is the migration of the antigen-loaded DC from the sites of infection toward the draining secondary lymphoid tissues. Although the specificity to migrate in response to the CCR7 ligand MIP-3b is the same for DC electroporated before and after maturation, we observed that the DC electroporated in a mature state were more mobile than DC electroporated in an immature state.
Ideally, the antigen of interest should be processed and presented by the DC in the context of both HLA class I and class II molecules.
50,51 Therefore, we chose to link the MAGE-A3 protein to the carboxy-terminal end of the Lamp1 protein, containing an HLA class II pathway sorting signal. When we electroporated mRNA encoding this chimeric protein into DC and cocultured them with MAGE-A3-specific HLA class II-restricted T cells, both immature and mature DC electroporated with sig-MAGE-A3-Lamp1 mRNA displayed a high T-cell stimulatory capacity. Both DC types have the ability to present the MAGE-A3 epitope to the specific T cells in vitro, but mature electroporated DC seem to be more potent inducers of T-cell activation than the immature electroporated DC. 52 This observation might be due to the fact that the mature electroporated DC express higher levels of costimulatory molecules, leading to an enhanced presentation of the antigen-derived epitope and an increased T-cell stimulatory capacity. These results seem somewhat in contrast to the findings of Van Tendeloo et al, 37 who showed that optimal antigen presentation was achieved when DC were electroporated prior to DC maturation. The authors attributed the lower T-cell stimulatory capacity of DC transfected after maturation to a lower transfection efficiency. This lower transfection efficiency could be due to the use of TNF-a and LPS as maturation agents. Immature DC electroporated with mRNA and subsequently matured by exposure to TNF-a and LPS result in a lower percentage of fully mature (CD83 + , HLA class II high ) DC than achieved with the maturation-inducing cytokine cocktail used in this study. Furthermore, we show that the HLA-DP4-restricted MAGE-A3 epitopes are efficiently processed and presented with a high stability by both electroporated DC and peptide-pulsed DC after maturation. In contrast, the presentation of a MAGE-A3 epitope by HLA class I molecules is short-lived by both mRNA-electroporated and peptide-pulsed DC. DC electroporated with mRNA seem to reach a significantly higher antigen presentation level at 24 h after antigen loading than that reached with peptide-pulsed DC. It has been described that during the maturation process, the synthesis of class II molecules is transiently upregulated and subsequently stopped, resulting in stable peptide class II complexes with extremely long half-lives. 53 In contrast, in DC, the HLA class I molecules have a short half-life that is not significantly affected by the maturation process. 54 The fact that high transgene mRNA levels are present in the DC electroporated after maturation, detectable for at least 72 h after transfection, indicates that the number of mRNA copies available for translation will not be a limiting factor. Moreover, DC electroporated after maturation contain transgene mRNA levels exceeding the levels found in tumor cells. 52 Recently, Liao et al 55 have reported that mature DC transfected with RNA using a nonlipid cationic reagent can efficiently induce tumorreactive CTL responses in vitro that are superior, in both frequency and TCR avidity, to those induced by peptidepulsed DC.
The finding that DC electroporated after maturation are more efficient in antigen presentation is, however, not reflected by their capacity to induce a primary MelanAspecific T-cell response in vitro. DC cryopreserved before and after electroporation are able to induce a similar MelanA-A2-specific T-cell response. However, further analysis is needed to determine whether mature electroporated DC are more immunogenic in vivo. An interesting study in mice 56 clearly indicates that DC electroporated after maturation are more potent inducers of an ovalbumin-specific CTL response in vivo when compared to DC electroporated before maturation.
Previous reports described that mRNA electroporation into immature DC does not influence the viability, the maturation capacity or the T-cell stimulatory capacity of these cells. 37, [39] [40] [41] We expand upon these reports and conclude that DC can also be electroporated at least as efficiently after maturation and that the immunophenotypical and functional characteristics of these mature electroporated DC are at least as good as those of the cells electroporated in the immature state. We also show that both immature and mature DC can be efficiently cryopreserved before or after electroporation without deleterious effects on viability, phenotype or T-cell stimulatory capacity including in vitro antigen-specific T-cell activation. Active immunotherapy using DC electroporated after maturation represents an improved and optimized approach, which is supported by their higher yield and stronger migratory and stimulatory capacity.
Materials and methods

Genetic constructs
The pGEM-eGFP vector was kindly provided by Dr E Gilboa (Duke University Medical Center, Durham, NC, USA). This plasmid contains a 741 bp eGFP-encoding fragment, flanked by the 5 0 and 3 0 untranslated regions of the Xenopus laevis b-globin gene and a polyA tail (A64). The transcription is controlled by a bacteriophage T7 promoter. SpeI and NotI sites are present at the 3 0 end of the A64 stretch to allow linearization of the plasmid before in vitro transcription.
The tNGFR (extracellular and transmembrane fragment) cDNA was amplified from the plasmid ptNGFR kindly provided by Dr C Traversari (Instituto Scientifico HSRaffaele, Milan, Italy). We used a PCR to insert a 5 0 BspHI site, spanning the start codon and at the 3 0 end, a stop codon and a BglII site. The eGFP gene was excised from pGEM-eGFP with NcoI and BamHI and replaced with a BspHI-BglII fragment containing the tNGFR gene.
Bonehill et al 52 described the construction of the pGEM-sig-MAGE-A3-Lamp1 plasmid.
The cDNA encoding the human melanoma-associated antigen MelanA was kindly provided by Dr P Coulie 
Production of in vitro-transcribed mRNA
Prior to in vitro transcription, the pGEM-eGFP, pGEMsig-MAGE-A3-Lamp1 and pGEM-sig-MelanA-Lamp1 plasmids were linearized with SpeI and the plasmid pGEM-tNGFR was linearized with NotI. The in vitro RNA transcription was performed with T7 RNA polymerase according to the manufacturer's instructions (Ambion mMESSAGE mMACHINEt kit, Austin, TX, USA). The production of full-length capped mRNA was confirmed by agarose gel electrophoresis and mRNA concentration was measured spectrophotometrically. mRNA samples were stored in small aliquots at À201C.
In vitro generation of monocyte-derived DC
PBMC were used as a source of DC precursors and isolated from leukapheresis products of healthy HLA-DP4/HLA-A1-or HLA-A2-positive donors. DC were generated according to the methods of Romani et al 15 with several modifications to increase DC yield. Briefly, CD14 + monocytes were enriched in a semiclosed culture system using double tray Cell Factories (NUNC, Naperville, IL, USA) as described previously.
14 The adherent fraction was cultured in RPMI 1640 medium (Cambrex, Verviers, Belgium) supplemented with 1% heat-inactivated autologous plasma (AP), 100 U/ml penicillin, 100 mg/ml streptomycin (PS; Cambrex), 0.24 mM Lasparagine, 0.55 mM L-arginine, 2 mM L-glutamine (AAG; Cambrex), 800 U/ml human GM-CSF (Leukomax; Novartis, Basel, Switzerland) and 100 U/ml IL-4 (BruCells, Brussels, Belgium) for 6 days. On days 2 and 4 of culture, medium containing the cytokine amount of day 0 was added. On day 5, a part of the immature DC were matured for 24 h using a maturation cocktail 16 containing 1000 U/ml IL-6 (home-made), 100 U/ml IL-1b (homemade), 100 U/ml TNF-a (Beromun, Boehringer Ingelheim Pharma, Germany) and 1 mg/ml PGE 2 (SigmaAldrich, St Louis, MO, USA). On day 6, immature and mature DC were harvested and electroporated or cryopreserved. The yield of immature and mature day 6 DC to input PBMC was analyzed by Trypan blue staining.
Electroporation of immature and mature DC
Immature and mature DC were harvested or thawed and electroporated by an optimized protocol 40 using the EQUIBIO EasyjecT Plus s apparatus (EQUIBIO, Ashford, UK). Immediately after transfection, immature DC were resuspended at 5 Â 10 5 DC/ml in prewarmed RPMI 1640 medium supplemented with 1% AP, PS, AAG, 800 U/ml GM-CSF and 100 U/ml IL-4. After 4 h, immature electroporated DC were matured for 24 or 48 h (as indicated) using the maturation cocktail. Mature electroporated cells were immediately diluted to a final concentration of 2.5 Â 10 5 DC/ml in their day 6 maturation medium for 24 h or more (as indicated). The viability and the yield of immature and mature DC to input DC 24 h after electroporation were determined by Trypan blue staining.
Cryopreservation of immature and mature DC
Immature and mature DC were slowly frozen before or after electroporation in cryotubes at 5-10 Â 10 6 DC/ml in AP with 10% DMSO (Sigma) and 2% glucose (Sterop, Brussels, Belgium) to À801C using a cryofreezing container (Cryo 11C freezing container, rate of cooling À11C/min; Nalgene, Hereford, UK). The cryotubes were transferred into liquid nitrogen and stored until use. Thawing of the cryopreserved DC was performed in a 371C water bath until small ice crystals were visible. Cold RPMI 1640 medium was added dropwise and the cells were pelleted in a precooled centrifuge (41C) and resuspended in prewarmed RPMI 1640 medium supplemented with 1% AP, PS, AAG, 800 U/ml GM-CSF and 100 U/ml IL-4. The viability of DC thawed before or after electroporation was determined by counting with Trypan blue after incubation at room temperature (RT) for 15-30 min. Before electroporation, thawed immature and mature DC were incubated for 2 h at 371C to recover.
Cell lines and clones
T2 cells (TAP-deficient, HLA-A2 + ) were cultured in IMDM medium (Gibco, Gaithersburg, MD, USA) supplemented with 10% FCS (Harlan Sera-Lab, Sussex, UK), PS and AAG.
A MAGE-A3-specific HLA-DP4-restricted T-cell clone (clone R12-C9; recognizing aa 243-258) and a MAGE-A3-specific HLA-A1-restricted T-cell clone (clone ESBI 648; recognizing aa 167-176) were cultured in IMDM medium supplemented with 10% human AB serum (PAA Laboratories, Linz, Austria), PS, AAG, 50 U/ml IL-2 (Chiron, Emeryville, CA, USA) and 5 ng/ml IL-7 (PeproTech, London, UK). The cells were restimulated weekly (clone ESBI 648) or every 2 weeks (clone R12-C9) with irradiated allogeneic LG2 EBV-B cells (1.5 Â 10 6 per 24 wells) as feeder cells and MZ2 melanoma cells preincubated with synthetic peptide (1 Â 10 5 per 24 wells) as stimulator cells.
Synthetic peptides and peptide pulsing of DC and T2 cells
The lyophilized synthetic peptides corresponding to the MAGE-A3 epitope presented in the context of HLA-DP4 (M3-DP4 peptide, aa 243-258; sequence KKLLTQHFVQENYLEY), HLA-A1 (M3-A1 peptide, aa 167-176; sequence EVDPIGHLY), HLA-A2 (M3-A2 peptide, aa 271-279; sequence FLWGPRALV) and the MelanA-A2 epitope presented in the context of HLA-A2 (MelanA-A2 peptide, aa 26-35; sequence EAAGI-GILTV) were dissolved in 100% DMSO (Sigma) to 20 mg/ml, further diluted in 10 mM acetic acid to a final concentration of 2 mg/ml and stored in aliquots at À201C.
T2 cells or mature DC were loaded at a cell density of 2 Â 10 6 cells/ml in serum-free IMDM medium with 10 mg/ml of the indicated peptide for 2 h at 371C. HLA class I-restricted peptide pulsing was supplemented with 2.5 mg/ml b2 microglobulin (purchased from Calbiochem, Darmstadt, Germany and dissolved at 250 mg/ml in PBS and stored at À201C). Afterwards, T2 cells or DC were subsequently washed and used as restimulator cells in IFN-g release assays.
Optimizing
Flow cytometry analysis
To analyze the eGFP expression, fresh or thawed DC were resuspended in FACSflow buffer at RT. Other stainings were performed for 30 min on ice in PBS containing 1% BSA and 0.02% NaN 3 and were preceded by blocking of FcR with 10% normal goat serum (Sigma). For immunophenotyping of DC, the following human mAb were used: anti-CD80, anti-CD83, anti-CD86, anti-CD25, anti-CD40 (BD PharMingen, San Jose, CA, USA), anti-HLA-DR (purified from clone L243) and anti-NGFR (purified from clone HB8738). All Ab were PE conjugated except anti-HLA-DR and anti-NGFR. The latter were biotin labeled and detected through streptavidin-PE (PharMingen) binding. CCR7 expression was determined by incubation with mouse anti-human CCR7 mAb, followed by incubation with rat anti-mouse IgM biotin-labeled mAb (PharMingen) and incubation with streptavidin-PE. Nonreactive isotype-matched Ab (PharMingen) were used as controls. Fluorescence analysis was performed with a FACSCalibur flow cytometer (Becton Dickinson) using CellQuest software (Becton Dickinson). Cells were electronically gated according to light scatter properties in order to exclude dead cells and contaminating lymphocytes.
Allogeneic mixed lymphocyte reaction
Fresh DC electroporated either before or after maturation were used for stimulation of allogeneic T cells. Briefly, 2 Â 10 5 nonadherent cells collected from freshly isolated PBMC and subsequently stored in liquid nitrogen were thawed and cocultured with graded numbers of electroporated DC in triplicate in 96-well round-bottom plates during 5 days. All the stimulator cells were used 24 h after electroporation. The proliferation assay was carried out in RPMI 1640 medium supplemented with 1% AP, PS and AAG. For the last 16 h of coculture, 1 mCi 3 H-methylthymidine (Amersham, Buckingham, UK) was added to determine allogeneic T-cell proliferation. As negative controls, responder T cells and stimulator DC were separately cultured in medium. Cells were harvested on glass filter paper and thymidine uptake was quantified by liquid scintillation counting (Microbeta, Wallac, Turku, Finland).
Human cytokine and chemokine production
To mimic the interaction with CD40L-expressing T cells, both immature and mature electroporated DC, stimulated for 24 or 48 h with a cocktail of proinflammatory cytokines, were harvested, washed and cocultured at a 1:1 ratio with 3T6 or 3T6 human CD40 ligand-(3T6-CD40L) transfected cells onto a 24-well plate in RMPI medium containing 1% AP or AB serum, PS, AAG and 1000 U/ml IFN-g (PeproTech). All DC were frozen before electroporation. Their capacity to secrete cytokines and chemokines after activation through CD40 ligation was evaluated in three replicate cultures. Supernatants were collected after 24 h and analyzed for IL-4 (Biosource, Camarillo, CA, USA), IFN-a, IL-8, IL-12p70 (Bender MedSystems, Vienna, Austria), IL-6, TNF-a (eBioscience, San Diego, CA, USA), MIP-1a, MIP-1b and MIP-3b (R&D Systems, Oxford, UK) content by ELISA following the manufacturer's instructions.
Migration assay
Chemotaxis of DC electroporated either before or after maturation was measured by migration through a polycarbonate filter with 5 mm pore size in 24-well Transwell chambers (Corning Costar, Elscolab, Belgium). Briefly, 600 ml of RPMI 1640 medium containing 1% AP, PS, AAG with MIP-3b (CCL19; 40 ng/ml, R&D Systems) or medium without MIP-3b for spontaneous migration was added to the lower chamber. A total of 1 Â 10 5 electroporated DC, unstimulated or stimulated for 24 or 48 h with a cocktail of proinflammatory cytokines, were washed and added to the upper chamber in a total volume of 100 ml. After an incubation period of 1.5 h at 371C, the medium in the lower chamber was harvested and concentrated to a volume of 200 ml and the number of migrated DC was counted manually or by flow cytometry using CellQuest software (Becton Dickinson). Each experiment was performed in duplicate.
Antigen presentation assays
To investigate the T-cell stimulatory capacity of the DC, frozen either before or after electroporation, 2 Â 10 4 sig-MAGE-A3-Lamp1 mRNA-electroporated DC or peptidepulsed DC were cocultured with 5 Â 10 3 M3-DP4-or M3-A1-specific T-cell clones in 200 ml IMDM supplemented with 10% human AB serum, PS, AAG and 25 U/ml IL-2. As negative controls, irrelevant mRNA-electroporated DC or irrelevant peptide-pulsed DC were used. Each coculture was performed in triplicate in 96-well roundbottom plates. After 20 h of coculture, the supernatant was harvested and assessed for the presence of IFN-g by ELISA using a commercially available kit (BioSource).
Quantitative PCR
Total RNA was extracted from electroporated DC by using a commercial kit (SV Total RNA Isolation System, Promega, Madison, WI, USA), according to the manufacturer's protocol. Total RNA (250 ng) was reversetranscribed with the Superscript First-Strand Synthesis System for RT-PCR kit (Invitrogen, Paisley, UK) according to the manufacturer's protocol. Expression of MAGE-A3 (GenBank U03735) was measured by quantitative PCR, based on TaqMan methodology, using the ABI PRISM 7700 Sequence Detection System (Applied Biosystems, Warrington, UK). Normalization of the samples was achieved by dividing the copy number of MAGE-A3 by that of the reference gene b-actin, as described previously by Bonehill et al.
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Induction of HLA-A2-restricted MelanA-specific T lymphocytes Both immature and mature DC electroporated with sigMelanA-Lamp1 mRNA, frozen either before or after electroporation, were analyzed for their capacity to stimulate MelanA-A2-specific T lymphocytes. Autologous nonadherent cells collected from PBMC of healthy HLA-A2-positive donors and stored in liquid nitrogen were used as a source of naive T cells. The electroporated DC were cocultured with T cells (DC:T cell ratio ¼ 1:10) in IMDM supplemented with 1% AP, PS, AAG, 20 U/ml IL-2 and 10 ng/ml IL-7. Effector T cells were restimulated weekly with the same stimulator DC as used in the primary stimulation. At 10 days after the second stimulation, effector cells were harvested, washed and 
Statistical analysis
Results are shown as mean7s.d. Comparison of results obtained for immature and mature electroporated DC was carried out using the two-tailed unpaired t-test. ANOVA was used when more than two groups were compared. Differences with Po0.05 were considered significant.
